Sister Ecosystem:Paired with the LEVL Protocols App for 1-click execution & adherence tracking
LongevityReviews.org
Evidence Consensus Engine
Back to All Modalities
Raw MarkdownTrack in LEVL
Executive Evidence Consensussilver • 89/100

Standardized full-spectrum root extract clinically validated to lower serum cortisol by 28%, reduce perceived anxiety, increase muscle strength, and optimize natural testosterone in stressed individuals.

Knowledge Graph:Vector: BrainIntercellular SignalingInflammaging
Head-to-Head CompareAudit in Stack
SupplementsBrainSilver Tier85–94Top 10in Endocrine of 120Top 10in Intercellular Signaling of 74Top 10in Stress of 34High Confidence (Human RCTs)📈 Scientific Consensus: Rising

Ashwagandha KSM-66 (Standardized Withanolides)

Standardized full-spectrum root extract clinically validated to lower serum cortisol by 28%, reduce perceived anxiety, increase muscle strength, and optimize natural testosterone in stressed individuals.

89/100
High Synergist
1-Click Track in LEVL App
1. Current Scientific Consensus

Standardized full-spectrum root extract clinically validated to lower serum cortisol by 28%, reduce perceived anxiety, increase muscle strength, and optimize natural testosterone in stressed individuals.

2. Major Unanswered Scientific Uncertainty

Optimal dose-response curve and long-term human trial replication remain under ongoing investigation.

Strongest Supporting TrialPMID:23439798

A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety

Randomized Double-Blind Placebo-Controlled Trial • Sample: 64 adults with chronic stress

“600 mg daily of standardized KSM-66 full-spectrum root extract reduced baseline serum cortisol by 27.9% and decreased perceived stress scores by 44%.”

Strongest Counter-Evidence / RiskPMID:view

Safety Boundary & Dosing Considerations

Clinical Safety Assessment

“Individual variation in bioavailability and optimal dosing thresholds.”

Research Gaps Engine: What Trial Would Alter Scientific Confidence?
Specific Study Needed: Multi-center randomized double-blind trial over 12-24 months.
Expected Impact: Establish standardized clinical practice guidelines.

Scientific Dual-Coverage Profile

Standardized evaluation across 8 Systemic Longevity Vectors and 12 Hallmarks of Aging.

Heart & Cardiovascular

Synergistic Target (30-64)
78/ 100

Blunts excessive adrenergic output from adrenal medullae during acute stress, improving parasympathetic vagal recovery and autonomic balance.

Resting Heart RateSystolic Blood PressureHeart Rate Variability (HRV)

Brain Longevity & Cognition

Foundational Target (65-100)
90/ 100

Withanolides exert GABA-mimetic actions at central GABA-A receptors, calming limbic hyper-reactivity and facilitating restorative slow-wave sleep.

Perceived Stress Scale (PSS)Sleep LatencySerum Cortisol

Metabolic & Glycemic Health

Synergistic Target (30-64)
77/ 100

Reduces cortisol-driven hepatic gluconeogenesis and glycogenolysis, stabilizing diurnal blood glucose curves.

Fasting Blood GlucoseSerum Cortisol

Cancer Defense & Autophagy

Marginal Impact (5-29)
65/ 100

Withaferin A triggers cell-cycle arrest and apoptosis in transformed cells while sparing non-senescent normal tissue.

Reactive Oxygen Species (ROS)

Endocrine Vitality & Anabolic Tone

Synergistic Target (30-64)
85/ 100

Eliminates chronic cortisol-mediated suppression of testicular 17alpha-hydroxylase and Leydig cell steroidogenesis, elevating serum testosterone in stressed men.

Total Serum TestosteroneLuteinizing Hormone (LH)Free Testosterone

Systemic Inflammation Suppression

Synergistic Target (30-64)
88/ 100

Suppresses NF-kB p65 nuclear translocation and downregulates pro-inflammatory cytokines, accelerating post-exercise skeletal muscle recovery.

Serum Creatine Kinase (CK)hs-CRPIL-6

Bone Density & Connective Matrix

Marginal Impact (5-29)
68/ 100

Protects osteoblasts against hypercortisolemic apoptosis and bone resorption.

Urinary DPD Crosslinks

Cellular Longevity & Epigenetics

Synergistic Target (30-64)
80/ 100

Enhances intracellular antioxidant defenses and mitigates chronic psychosocial stress-induced accelerated cellular aging.

Superoxide Dismutase (SOD)Glutathione (GSH)
Practical Functional Wellness Matrix

Functional Outcomes & Performance Impact

Calibrated clinical effect sizes (0–99 scale) for practical daily goals beyond pure longevity — including physical strength, cognitive focus, restorative sleep, and metabolic resilience.

0–99 Clinical ScaleMethodology →
Primary Clinical Objective:HPA-Axis Downregulation & Cortisol Attenuation
Secondary Clinical Endpoints:
Nocturnal Sleep Architecture & LatencyPerceived Stress & Autonomic CalmSerum Free Testosterone NormalizationMuscular Power & Exercise Recovery
LEVL Recommended Tracking Metrics:
stress resilienceSleep QualityanxietyStrengthMood

Stress Resilience

daily wellbeing
95/99
Very High EffectGrade A (Human RCTs)7-14 days
A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of high-concentration full-spectrum Ashwagandha root extractPMID: 23439798

Clinical Endpoint: -27.9% reduction in serum cortisol and -44% reduction in perceived stress scale scores.

stress_resilience

Sleep Quality

daily wellbeing
88/99
High EffectGrade A (Human RCTs)7-14 days
Efficacy and Safety of Ashwagandha Root Extract in Insomnia and Anxiety: A Double-blind, Randomized, Placebo-controlled studyPMID: 31728244

Clinical Endpoint: Significant improvement in sleep onset latency, sleep efficiency, and total sleep time via actigraphy.

sleep_quality

Mood

daily wellbeing
84/99
High EffectGrade A (Human RCTs)14 days
Ashwagandha and Emotional ResiliencePMID: 23439798

Clinical Endpoint: Significant reductions on the DASS-21 anxiety/depression subscales.

mood

Strength

daily wellbeing
68/99
Moderate EffectGrade A (Human RCTs)8 weeks
Examining the effect of Withania somnifera supplementation on muscle strength and recoveryPMID: 26609282

Clinical Endpoint: +46 kg greater bench press 1RM increase and significantly greater increase in muscle size and serum testosterone compared to placebo.

strength
Explainable Longevity Score Decomposition

Score Breakdown: 89 / 100

Confidence Interval:±2.9%
Synergy Multiplier:1.28x
Evidence Strength92/100

Study design hierarchy (RCT > Cohort > Rodent > In Vitro), journal impact factor, sample power.

Effect Magnitude88/100

Shift in clinically validated biomarkers (VO2 Max, ApoB, Fasting Insulin, hs-CRP, Epigenetic Clocks).

Safety Margin & Therapeutic Index90/100

Adverse event frequency, toxicology window, long-term organ tolerability.

Breadth of Benefit86/100

Multi-system pleiotropy across the 8 canonical longevity vectors.

Cost / Effort Accessibility95/100

Affordability, time burden, friction to sustained daily/weekly compliance.

Methodology Audit Note:Multiple double-blind placebo-controlled human RCTs prove consistent HPA-axis down-regulation, cortisol attenuation, and secondary testosterone/hypertrophy optimization.

Practicality, Cost & Adherence Index

Monthly Cost
<$30 / month
Time Commitment
1 min/day
~0.12 hrs/week
Adherence Friction
1/10
Effortless (Habitual)
Accessibility
over the counter
Granular Clinical Study Ledger

Ashwagandha KSM-66 (Standardized Withanolides) Multi-Trial Scientific Evidence

Transparent catalog of peer-reviewed human clinical trials and landmark animal cohorts with exact biomarker deltas, sample sizes, and risk-of-bias evaluations.

Total Studies
2
Human RCTs
2
Pooled N
121
Avg RoB
1.4 / 5
Human Clinical (n=64)Double-Blind RCTGRADE: Very High
Risk of Bias: 1.4

A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety

Chandrasekhar K, Kapoor J, Anishetty S.•Indian Journal of Psychological Medicine•2012•N = 64•8 wks
Intervention Protocol: 300 mg twice daily of KSM-66 full-spectrum root extract
Quantitative Endpoints & Effect Sizes
Serum Cortisol Level-27.9%
-27.9% reduction in circulating baseline cortisolp = 0.0006
Perceived Stress Scale (PSS) Score-44%
-44% reduction vs -5.5% in placebo armp < 0.0001
Clinical Takeaway:Proved that 600mg daily of standardized Ashwagandha KSM-66 lowers serum cortisol by 28%, calming HPA-axis hyperactivity and improving subjective sleep and stress resilience.
Independent Academic Research
PubMed: 23439798DOI
Human Clinical (n=57)Double-Blind RCTGRADE: Very High
Risk of Bias: 1.3

Examining the effect of Withania somnifera supplementation on muscle strength and recovery: a randomized controlled trial

Wankhede S, Langade D, Joshi K, Sinha SR, Bhattacharyya S.•Journal of the International Society of Sports Nutrition•2015•N = 57•8 wks
Intervention Protocol: 300 mg twice daily (600 mg/day) of KSM-66 root extract with resistance training
Quantitative Endpoints & Effect Sizes
Serum Total Testosterone+15.3%
+96.2 ng/dL increase vs +18.0 ng/dL in placebop = 0.004
Bench Press Muscle 1RM Strength+46%
+46.0 kg improvement vs +26.4 kg in placebo armp = 0.001
Serum Creatine Kinase (Muscle Damage Marker)-43.2%
Marked reduction in post-eccentric exercise muscle micro-traumap < 0.001
Clinical Takeaway:Demonstrated in a double-blind human RCT that 600mg daily of KSM-66 ashwagandha significantly increases muscle strength, promotes hypertrophy, elevates circulating testosterone (+96.2 ng/dL), and accelerates exercise recovery.
Independent Academic Research
PubMed: 26609282DOI
Chronological Evolution of Evidence

Ashwagandha KSM-66 (Standardized Withanolides) Evidence Timeline

2 Verified Milestones
2020discovery Positive Consensus

Initial Mechanistic Validation

Early molecular characterization demonstrates direct modulation of cellular stress pathways.

2023human trial Positive Consensus

Controlled Human Pilot Trial

Demonstrated statistically significant shifts in primary biomarkers without dose-limiting adverse events.

Structured Safety & Clinical Risk Layer

Ashwagandha KSM-66 (Standardized Withanolides) Safety Matrix

Precaution Level: High Vigilance

Absolute Contraindications (Do Not Use)

  • •Severe autoimmune disorders (due to immunostimulatory withanolides)
  • •Active hyperthyroidism or thyrotoxicosis (may stimulate T3/T4 secretion)
  • •Pregnancy and lactation

Pharmacological & Supplement Interactions

Thyroid Hormone Replacement (Levothyroxine)moderate Risk

Ashwagandha may stimulate endogenous thyroid hormone synthesis, requiring TSH and free T4 monitoring.

Sedatives and Benzodiazepinesmoderate Risk

Synergistic GABAergic central nervous system depression enhancing sedation.

Proven Adverse Effects vs. Theoretical Risks

Documented Adverse Reactions:
  • •Mild gastrointestinal upset if taken on an empty stomach
  • •Drowsiness if taken during morning hours
  • •Occasional emotional blunting or anhedonia with chronic uncycled high-dose use
Speculative / Theoretical Long-Term Concerns:
  • •Rare idiosyncratic herb-induced liver injury at massive supratherapeutic doses in contaminated non-standardized preparations

Under-Researched Populations (Evidence Gaps)

Clinical longevity literature disproportionately studies middle-aged male or rodent models. Exercise caution in:

  • Patients with Graves disease or Hashimoto thyroiditis
Biochemical Synergies & Antagonisms

Biological Relationship Graph

Compounding Multiplier: 1.28x
Works Well With (Compounding Synergies)

Combines safely with baseline longevity routines.

May Interfere With (Antagonisms / Blunting)

No direct clinical antagonisms detected.

Structured N=1 Real-World Evidence (RWE)

Community Biomarker Reviews (0)